Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Dasatinib + Quercetin (Senolytic Stack) | Resveratrol | |
|---|---|---|
| Category | Pharmaceuticals | Supplements |
| Standard Dose | Research indicates Dasatinib 100 mg + Quercetin 1000-1250 mg orally for 2 consecutive days, repeated every 2-4 weeks (intermittent 'hit-and-run' dosing). | 250-500mg trans-resveratrol daily |
| Timing | Take both compounds together on dosing days, with or without food. The 'hit-and-run' approach exploits the fact that senolytic effect occurs rapidly but senescent cells take weeks to re-accumulate. Quercetin bioavailability is improved by fat co-ingestion. | Morning with a fat-containing meal. Often taken alongside NMN for synergistic sirtuin activation. |
| Cycle Duration | Ongoing intermittent cycles. Long-term safety data in healthy populations is limited. Typically used in periodic courses (e.g., 2 days per month for 3-6 months, then reassess). | ongoing |
| Evidence Level | moderate_human | moderate_human |
Dasatinib is a multi-kinase inhibitor (targeting SRC, ABL, c-KIT, PDGFR, and ephrin receptors) originally developed for chronic myeloid leukemia. Quercetin is a natural flavonoid that inhibits PI3K, serpine/PAI-2, BCL-xL, and other anti-apoptotic pathways. Together, they constitute a senolytic combination that selectively induces apoptosis in senescent cells by disabling the senescent cell anti-apoptotic pathways (SCAPs) that allow damaged, non-dividing cells to resist programmed cell death. Senescent cells accumulate with aging and secrete the SASP (senescence-associated secretory phenotype) — inflammatory cytokines, matrix metalloproteinases, and growth factors that drive tissue dysfunction. By clearing senescent cells, D+Q reduces SASP-driven chronic inflammation.
Research indicates Dasatinib 100 mg + Quercetin 1000-1250 mg orally for 2 consecutive days, repeated every 2-4 weeks (intermittent 'hit-and-run' dosing).
Take both compounds together on dosing days, with or without food. The 'hit-and-run' approach exploits the fact that senolytic effect occurs rapidly but senescent cells take weeks to re-accumulate. Quercetin bioavailability is improved by fat co-ingestion.
Ongoing intermittent cycles. Long-term safety data in healthy populations is limited. Typically used in periodic courses (e.g., 2 days per month for 3-6 months, then reassess).
Resveratrol activates SIRT1 (the longevity sirtuin) via allosteric binding, promoting deacetylation of PGC-1alpha (mitochondrial biogenesis), FOXO3 (stress resistance), and p53 (DNA repair). It inhibits NF-kB and COX-2, reducing chronic inflammation. Resveratrol also activates AMPK independently of SIRT1 and inhibits phosphodiesterases (PDEs), raising cAMP levels. It improves endothelial function via eNOS upregulation and NO production.
250-500mg trans-resveratrol daily
Morning with a fat-containing meal. Often taken alongside NMN for synergistic sirtuin activation.
ongoing
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →